11月24日，卫宁健康涨5.23%，截至发稿，报8.45元/股，成交4.95亿元，换手率3.13%，总市值187.14亿 元。 资料显示，卫宁健康科技集团股份有限公司位于上海市静安区寿阳路99弄9号卫宁健康大厦，成立日期 2004年4月7日，上市日期2011年8月18日，公司主营业务涉及医疗软件研究开发、销售与技术服务业务, 并为医疗卫生行业信息化提供整体解决方案。主营业务收入构成为：软件及服务84.65%，硬件销售 7.89%，互联网医疗健康7.46%，其他0.00%。 前海联合泳隽混合A（004693）成立日期2018年1月29日，最新规模92.72万。今年以来收益5.45%，同 类排名6341/8209；近一年收益1.74%，同类排名7392/8129；成立以来收益59.16%。 前海联合泳隽混合A（004693）基金经理为张永任。 截至发稿，张永任累计任职时间5年198天，现任基金资产总规模1.64亿元，任职期间最佳基金回报 47.46%， 任职期间最差基金回报-23.73%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标 ...

分红方面，卫宁健康A股上市后累计派现4.55亿元。近三年，累计派现9722.63万元。 今年以来卫宁健康已经2次登上龙虎榜，最近一次登上龙虎榜为2月7日。 机构持仓方面，截止2025年9月30日，卫宁健康十大流通股东中，华宝中证医疗ETF（512170）位居第 三大流通股东，持股5007.72万股，相比上期减少869.61万股。易方达创业板ETF（159915）位居第五大 流通股东，持股3872.61万股，相比上期减少653.76万股。诺安成长混合A（320007）位居第十大流通股 东，持股1689.10万股，为新进股东。招商优势企业混合A（217021）退出十大流通股东之列。 资料显示，卫宁健康科技集团股份有限公司位于上海市静安区寿阳路99弄9号卫宁健康大厦，成立日期 2004年4月7日，上市日期2011年8月18日，公司主营业务涉及医疗软件研究开发、销售与技术服务业务, 并为医疗卫生行业信息化提供整体解决方案。主营业务收入构成为：软件及服务84.65%，硬件销售 7.89%，互联网医疗健康7.46%，其他0.00%。 责任编辑：小浪快报 11月24日，卫宁健康盘中上涨2.24%，截至10:26，报8.21 ...

Core Viewpoint - The stock of Weining Health has experienced a decline in recent trading sessions, with a notable drop of 11.55% over the last five days, despite a year-to-date increase of 13.65% [1][2] Group 1: Stock Performance - As of November 11, Weining Health's stock price was 8.12 CNY per share, with a market capitalization of 17.983 billion CNY [1] - The stock has seen a significant decline of 23.18% over the past 60 days [1] - The company has appeared on the trading leaderboard twice this year, with the most recent occurrence on February 7 [1] Group 2: Financial Performance - For the period from January to September 2025, Weining Health reported a revenue of 1.296 billion CNY, a decrease of 32.27% year-on-year [2] - The net profit attributable to shareholders was -241 million CNY, reflecting a substantial decline of 256.10% compared to the previous year [2] Group 3: Shareholder Information - As of October 31, the number of Weining Health's shareholders was 114,100, an increase of 0.47% from the previous period [2] - The average number of circulating shares per shareholder decreased by 0.46% to 16,781 shares [2] - The company has distributed a total of 455 million CNY in dividends since its A-share listing, with 97.226 million CNY distributed over the last three years [3] Group 4: Institutional Holdings - As of September 30, 2025, the top ten circulating shareholders included Huabao Zhongzheng Medical ETF, which held 50.0772 million shares, a decrease of 8.6961 million shares from the previous period [3] - The E Fund Growth Mixed A fund entered the top ten shareholders with a holding of 16.891 million shares [3]

Core Viewpoint - The stock of Weining Health has shown a mixed performance in recent trading sessions, with a year-to-date increase of 25.82% but a decline in the last five, twenty, and sixty days [1][2]. Financial Performance - As of September 30, Weining Health reported a revenue of 839 million yuan for the first half of 2025, representing a year-on-year decrease of 31.43%. The net profit attributable to shareholders was -118 million yuan, a significant decline of 491.04% compared to the previous year [2]. - Cumulative cash dividends since the A-share listing amount to 455 million yuan, with 97.23 million yuan distributed over the last three years [3]. Shareholder Information - The number of shareholders as of September 30 is 117,300, a decrease of 0.45% from the previous period. The average number of tradable shares per person increased by 0.49% to 16,323 shares [2]. - As of June 30, 2025, the top ten circulating shareholders include Huabao Zhongzheng Medical ETF and E Fund Growth Enterprise ETF, with notable changes in their holdings [3]. Stock Market Activity - On October 15, Weining Health's stock price rose by 2.04% to 8.99 yuan per share, with a trading volume of approximately 99.64 million yuan and a turnover rate of 0.58%. The total market capitalization stands at 19.91 billion yuan [1]. - The stock has appeared on the "Dragon and Tiger List" twice this year, with the most recent occurrence on February 7 [1].

Core Viewpoint - The stock of Weining Health has experienced a decline in recent trading sessions, with a notable drop in both revenue and net profit for the first half of 2025, indicating potential challenges for the company moving forward [1][2]. Company Overview - Weining Health Technology Group Co., Ltd. is based in Shanghai and was established on April 7, 2004, with its listing date on August 18, 2011. The company specializes in the research, development, sales, and technical services of medical software, providing comprehensive solutions for the healthcare industry's information technology [1]. - The main revenue composition of the company includes software and services (84.65%), hardware sales (7.89%), and internet healthcare (7.46%) [1]. Financial Performance - As of September 30, Weining Health reported a revenue of 839 million yuan for the first half of 2025, representing a year-on-year decrease of 31.43%. The net profit attributable to the parent company was -118 million yuan, a significant decline of 491.04% compared to the previous year [2]. - The company has cumulatively distributed 455 million yuan in dividends since its A-share listing, with 97.23 million yuan distributed over the past three years [3]. Shareholder Information - As of June 30, 2025, Weining Health had 117,300 shareholders, a decrease of 0.45% from the previous period. The average number of circulating shares per shareholder increased by 0.49% to 16,323 shares [2]. - The top circulating shareholders include Huabao Zhongzheng Medical ETF, which holds 58.77 million shares, and Yifangda Growth Enterprise Board ETF, holding 45.26 million shares, with some changes in their holdings compared to the previous period [3].

Core Viewpoint - The stock of Weining Health has shown a significant increase in price this year, with a year-to-date rise of 31.42%, despite recent fluctuations in trading volume and net capital outflow [1][2]. Financial Performance - For the first half of 2025, Weining Health reported a revenue of 839 million yuan, representing a year-on-year decrease of 31.43%. The net profit attributable to shareholders was -118 million yuan, a significant decline of 491.04% compared to the previous year [2]. - Cumulatively, Weining Health has distributed 455 million yuan in dividends since its A-share listing, with 97.23 million yuan distributed over the last three years [3]. Shareholder Structure - As of September 19, 2025, the number of shareholders for Weining Health was 117,800, a decrease of 0.53% from the previous period. The average number of circulating shares per person increased by 0.53% to 16,244 shares [2]. - The top ten circulating shareholders include notable entities such as Huabao Zhongzheng Medical ETF and E Fund Growth Enterprise Board ETF, with changes in their holdings noted [3].

Core Viewpoint - Yingkang Life's stock price increased by 1.78% on September 30, with a trading volume of 124 million yuan, indicating positive market sentiment towards the company [1]. Financing Summary - On September 30, Yingkang Life had a financing buy-in amount of 13.63 million yuan and a financing repayment of 27.28 million yuan, resulting in a net financing outflow of 13.65 million yuan [1]. - As of September 30, the total financing and securities lending balance for Yingkang Life was 269 million yuan, which accounts for 3.67% of its market capitalization, indicating a high level of financing activity compared to the past year [1]. - The company had a securities lending repayment of 16,800 shares and a securities lending sell-out of 200 shares, with a sell-out amount of 2,284 yuan, reflecting low securities lending activity [1]. Company Overview - Yingkang Life Technology Co., Ltd. is located in Qingdao, Shandong Province, and was established on August 6, 1998, with its listing date on December 9, 2010 [2]. - The company's main business involves medical devices and medical services, with a focus on developing, producing, and selling advanced radiation therapy equipment and establishing a specialized cancer treatment service network [2]. - The revenue composition of Yingkang Life includes 77.47% from medical services and 22.53% from medical devices and consumables [2]. Financial Performance - For the first half of 2025, Yingkang Life reported a revenue of 843 million yuan, representing a year-on-year growth of 2.40%, and a net profit attributable to shareholders of 61.83 million yuan, which is a 12.82% increase compared to the previous year [2]. Dividend Information - Since its A-share listing, Yingkang Life has distributed a total of 29.48 million yuan in dividends, with no dividends paid in the last three years [3].

Core Viewpoint - The stock of Weining Health has shown fluctuations in recent trading sessions, with a notable increase of 2.05% on September 24, 2023, while the company faces a significant decline in revenue and profit for the first half of 2025 [1][2]. Group 1: Stock Performance - As of September 24, 2023, Weining Health's stock price reached 8.96 CNY per share, with a market capitalization of 19.836 billion CNY [1]. - The stock has increased by 25.40% year-to-date, but has seen declines of 4.38% over the last five trading days, 15.39% over the last twenty days, and 10.22% over the last sixty days [1]. Group 2: Financial Performance - For the first half of 2025, Weining Health reported a revenue of 839 million CNY, a decrease of 31.43% year-on-year, and a net profit of -118 million CNY, representing a decline of 491.04% [2]. - The company has distributed a total of 455 million CNY in dividends since its A-share listing, with 97.226 million CNY distributed over the last three years [3]. Group 3: Shareholder Information - As of September 19, 2023, the number of Weining Health's shareholders was 117,800, a decrease of 0.53% from the previous period, while the average number of circulating shares per person increased by 0.53% to 16,244 shares [2]. - The top three circulating shareholders include Huabao Zhongzheng Medical ETF, which increased its holdings by 1.7506 million shares, and Yifangda Growth Enterprise ETF, which decreased its holdings by 652,300 shares [3].

Company Overview - Yingkang Life Technology Co., Ltd. is located in Qingdao, Shandong Province, and was established on August 6, 1998, with its listing date on December 9, 2010 [1] - The company primarily operates in the medical device and medical services sectors, focusing on the research, production, and sales of advanced medical equipment such as the Maxip radiation therapy equipment and Gamma Knife [1] - The revenue composition of the company is 77.47% from medical services, with 22.53% from equipment and consumables, and another 22.53% from medical devices [1] Stock Performance - On September 23, Yingkang Life's stock fell by 5%, trading at 11.02 CNY per share, with a total transaction volume of 92.35 million CNY and a turnover rate of 1.27%, resulting in a total market capitalization of 8.259 billion CNY [1] Fund Holdings - According to data from the top ten holdings of funds, one fund under Galaxy Fund has a significant position in Yingkang Life [2] - The Galaxy Kangle Stock A fund (519673) increased its holdings by 184,000 shares in the second quarter, bringing its total to 930,900 shares, which accounts for 5.06% of the fund's net value, making it the sixth-largest holding [2] - The fund has experienced a floating loss of approximately 539,900 CNY as of the latest report [2] Fund Manager Information - The fund manager of Galaxy Kangle Stock A is Fang Wei, who has been in the position for 4 years and 138 days [3] - The total asset size of the fund is 671 million CNY, with the best and worst fund returns during the manager's tenure being -4.55% and -18.43%, respectively [3]

Group 1 - The core viewpoint of the news highlights the recent trading performance and financial metrics of Weining Health, indicating a significant increase in financing activities and a notable decline in revenue and profit [1][2]. - On September 11, Weining Health's stock rose by 1.93%, with a trading volume of 454 million yuan, and a net financing purchase of 3.59 million yuan [1]. - As of September 11, the total financing and securities lending balance for Weining Health reached 1.397 billion yuan, with financing balance accounting for 6.62% of the circulating market value, indicating a high level compared to the past year [1]. Group 2 - For the first half of 2025, Weining Health reported a revenue of 839 million yuan, representing a year-on-year decrease of 31.43%, and a net profit attributable to shareholders of -118 million yuan, a significant decline of 491.04% [2]. - The company has distributed a total of 455 million yuan in dividends since its A-share listing, with 97.23 million yuan distributed over the past three years [3]. - As of June 30, 2025, the top ten circulating shareholders of Weining Health included notable institutional investors, with changes in their holdings reflecting market dynamics [3].